HRP20230576T1 - Rekombinantna ljudska kisela alfa-glukozidaza - Google Patents
Rekombinantna ljudska kisela alfa-glukozidaza Download PDFInfo
- Publication number
- HRP20230576T1 HRP20230576T1 HRP20230576TT HRP20230576T HRP20230576T1 HR P20230576 T1 HRP20230576 T1 HR P20230576T1 HR P20230576T T HRP20230576T T HR P20230576TT HR P20230576 T HRP20230576 T HR P20230576T HR P20230576 T1 HRP20230576 T1 HR P20230576T1
- Authority
- HR
- Croatia
- Prior art keywords
- rhgaa
- moles
- subject
- potential
- use according
- Prior art date
Links
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 title claims 24
- 102000045921 human GAA Human genes 0.000 title claims 24
- 230000004988 N-glycosylation Effects 0.000 claims 8
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 5
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 5
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 claims 3
- 229960001512 miglustat Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 102000004420 Creatine Kinase Human genes 0.000 claims 2
- 108010042126 Creatine kinase Proteins 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims 1
- ZAIHWUXYHDAQEV-YXTXVXLGSA-N P(=O)(O)(O)O.O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO Chemical compound P(=O)(O)(O)O.O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO ZAIHWUXYHDAQEV-YXTXVXLGSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000002535 acidifier Substances 0.000 claims 1
- 230000003113 alkalizing effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102000016679 alpha-Glucosidases Human genes 0.000 claims 1
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000004502 glycogen storage disease II Diseases 0.000 claims 1
- -1 hexose tetrasaccharide Chemical class 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims 1
- 230000004199 lung function Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000004885 tandem mass spectrometry Methods 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Claims (9)
1. Pripravak koji sadrži populaciju molekula rekombinantne ljudske kisele α-glukozidaze (rhGAA) za upotrebu u liječenju Pompeove bolesti kod subjekta kojem je to potrebno, pri čemu su molekule rhGAA proizvedene iz stanica jajnika kineskog hrčka (CHO);
pri čemu molekule rhGAA sadrže sedam potencijalnih N-glikozilacijskih mjesta;
pri čemu molekule rhGAA u prosjeku sadrže 3-4 ostatka manoza-6-fosfata (M6P);
pri čemu molekule rhGAA u prosjeku sadrže najmanje oko 0,5 mola bis-manoza-6-fosfata (bis-M6P) po molu rhGAA na prvom potencijalnom mjestu N-glikozilacije kako je određeno uporabom tekućinske kromatografije-tandem masene spektrometrije (LC-MS/MS);
pri čemu se populacija rhGAA molekula primjenjuje istovremeno ili uzastopno s farmakološkim pratiocem, i pri čemu je farmakološki pratilac miglustat ili njegova farmaceutski prihvatljiva sol;
pri čemu se populacija rhGAA molekula primjenjuje intravenozno u dozi od oko 20 mg/kg, a miglustat ili njegova farmaceutski prihvatljiva sol se primjenjuje oralno u dozi od oko 260 mg; i pri čemu
(i) subjekt je pacijent s prebacivanjem na ERT, i, u usporedbi s osnovnom vrijednošću, subjektova plućna funkcija, mjerena testom uspravnog forsiranog vitalnog kapaciteta (FVC), stabilna je ili poboljšana šest mjeseci nakon liječenja; i/ili
(ii) subjekt je ambulantni pacijent s prebacivanjem na ERT i, u usporedbi s osnovnom vrijednošću, subjektova razina kreatin kinaze šest mjeseci nakon tretmana smanjena je za najmanje 15%; i/ili
(iii) subjekt je ne ambulantni pacijent s prebacivanjem na ERT i, u usporedbi s osnovnom vrijednošću, subjektova razina kreatin kinaze šest mjeseci nakon tretmana smanjena je za najmanje 20%; i/ili
(iv) subjekt je pacijent s prebacivanjem na ERT, i, u usporedbi s početnom vrijednošću, razine heksoza tetrasaharida u urinu subjekta šest mjeseci nakon liječenja smanjene su za najmanje 35%.
2. Pripravak za upotrebu prema zahtjevu 1, naznačen time što se miglustat ili njegova farmaceutski prihvatljiva sol primjenjuje prije primjene rhGAA.
3. Pripravak za upotrebu prema zahtjevu 1 ili zahtjevu 2, naznačen time što molekule rhGAA sadrže sekvencu aminokiselina najmanje 95% identičnu sa SEQ ID NO:1 ili SEQ ID NO:5.
4. Pripravak za upotrebu prema bilo kojem od zahtjeva 1 do 3, naznačen time što molekule rhGAA sadrže u prosjeku od oko 0,5 mola do oko 7,0 mola mono-M6P ili bis-M6P po molu rhGAA, kako je određeno pomoću LC-MS/MS.
5. Pripravak za upotrebu prema bilo kojem od zahtjeva 1 do 4, naznačen time što molekule rhGAA sadrže u prosjeku najmanje 2,5 mol M6P po molu rhGAA i najmanje 4 mol sijalinske kiseline po molu rhGAA, kako je određeno pomoću LC-MS/MS.
6. Pripravak za upotrebu prema bilo kojem od zahtjeva 1 do 5, naznačen time što, po molu rhGAA, molekule rhGAA sadrže u prosjeku:
(a) oko 0,4 do oko 0,6 mola mono-M6P na drugom potencijalnom mjestu N-glikozilacije;
(b) oko 0,4 do oko 0,6 mola bis-M6P na četvrtom potencijalnom mjestu N-glikozilacije; i
(c) oko 0,3 do oko 0,4 mola mono-M6P na četvrtom potencijalnom mjestu N-glikozilacije; pri čemu su (a)-(c) određeni pomoću LC-MS/MS.
7. Pripravak za upotrebu prema bilo kojem od zahtjeva 1to 6, naznačen time što, po molu rhGAA, molekule rhGAA nadalje sadrže oko 4 mola do oko 7,3 mola sijalinske kiseline; i
pri čemu, po molu rhGAA, molekule rhGAA sadrže u prosjeku:
(a) oko 0,9 do oko 1,2 mola sijalinske kiseline na trećem potencijalnom mjestu N-glikozilacije;
(b) oko 0,8 do oko 0,9 mola sijalinske kiseline na petom potencijalnom mjestu N-glikozilacije; i
(c) oko 1,5 do oko 4,2 mola sijalinske kiseline na šestom potencijalnom mjestu N-glikozilacije;
pri čemu su (a)-(c) određeni pomoću LC-MS/MS.
8. Pripravak za upotrebu prema bilo kojem od zahtjeva 1 do 7, naznačen time što je populacija rhGAA molekula formulirana u farmaceutskom pripravku, i pri čemu farmaceutski pripravak nadalje sadrži najmanje jedan pufer odabran iz skupine koja se sastoji od citrata, fosfata, i njihove kombinacije, te najmanje jednu pomoćnu tvar odabranu iz skupine koju čine manitol, polisorbat 80 i njihova kombinacija; pri čemu farmaceutski pripravak ima pH od oko 5,0 do oko 7,0.
9. Pripravak za upotrebu prema bilo kojem od zahtjeva 1 do 8, naznačen time što, je u farmaceutskom pripravku populacija molekula rhGAA prisutna u koncentraciji od oko 5-50 mg/mL, najmanje jedan pufer je natrijev citratni pufer prisutan u koncentraciji od oko 10-100 mM, najmanje jedna pomoćnu tvar je manitol prisutan u koncentraciji od oko 10-50 mg/mL i polisorbat 80 je prisutan u koncentraciji od oko 0.1-1 mg/mL, te farmaceutski pripravak nadalje sadrži vodu i izborno sadrži sredstvo za zakiseljavanje i/ili sredstvo za alkalizaciju; pri čemu farmaceutski pripravak ima pH od oko 6,0.
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506561P | 2017-05-15 | 2017-05-15 | |
| US201762506569P | 2017-05-15 | 2017-05-15 | |
| US201762506574P | 2017-05-15 | 2017-05-15 | |
| US201762529300P | 2017-07-06 | 2017-07-06 | |
| US201762564083P | 2017-09-27 | 2017-09-27 | |
| US201762567334P | 2017-10-03 | 2017-10-03 | |
| US201862618021P | 2018-01-16 | 2018-01-16 | |
| US201862624638P | 2018-01-31 | 2018-01-31 | |
| US201862660758P | 2018-04-20 | 2018-04-20 | |
| EP18802722.1A EP3624831B1 (en) | 2017-05-15 | 2018-05-15 | Recombinant human acid alpha-glucosidase |
| PCT/US2018/032815 WO2018213340A1 (en) | 2017-05-15 | 2018-05-15 | Recombinant human acid alpha-glucosidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230576T1 true HRP20230576T1 (hr) | 2023-09-01 |
Family
ID=64274660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230576TT HRP20230576T1 (hr) | 2017-05-15 | 2018-05-15 | Rekombinantna ljudska kisela alfa-glukozidaza |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20210393747A1 (hr) |
| EP (2) | EP4223310A3 (hr) |
| JP (2) | JP7193476B2 (hr) |
| KR (1) | KR20200004414A (hr) |
| CN (1) | CN111356474A (hr) |
| AU (1) | AU2018270925A1 (hr) |
| BR (1) | BR112019024125A2 (hr) |
| CA (1) | CA3063615A1 (hr) |
| CL (1) | CL2019003251A1 (hr) |
| DK (1) | DK3624831T5 (hr) |
| ES (1) | ES2950808T3 (hr) |
| FI (1) | FI3624831T3 (hr) |
| HR (1) | HRP20230576T1 (hr) |
| HU (1) | HUE062504T2 (hr) |
| IL (2) | IL270530B2 (hr) |
| LT (1) | LT3624831T (hr) |
| MX (1) | MX2019013624A (hr) |
| PL (1) | PL3624831T3 (hr) |
| PT (1) | PT3624831T (hr) |
| RS (1) | RS64301B1 (hr) |
| SI (1) | SI3624831T1 (hr) |
| TW (1) | TW201900208A (hr) |
| WO (1) | WO2018213340A1 (hr) |
| ZA (1) | ZA201907552B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ760232A (en) | 2017-06-07 | 2023-05-26 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| EP3871687A1 (en) * | 2020-02-27 | 2021-09-01 | eleva GmbH | Enzyme replacement therapy for treating pompe disease |
| IL305103A (en) * | 2021-02-11 | 2023-10-01 | Amicus Therapeutics Inc | Recombinant human acid alpha glucosidase and uses thereof |
| CN114280182A (zh) * | 2021-12-23 | 2022-04-05 | 福建省中医药科学院 | 一种太子参均一多糖的hplc-fld检测方法 |
| WO2023150387A1 (en) * | 2022-02-07 | 2023-08-10 | M6P Therapeutics, Inc. | Compositions comprising acid alpha glucosidase and methods of use thereof |
| WO2023215865A1 (en) * | 2022-05-05 | 2023-11-09 | Amicus Therapeutics, Inc. | Methods for treating pompe disease |
| WO2024119070A1 (en) * | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Methods for treating late onset pompe disease in pediatric patients |
| WO2024119091A1 (en) * | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Fexamethods for treating infantile-onset pompe disease in pediatric patients |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
| PT3470077T (pt) | 2008-02-12 | 2020-11-30 | Amicus Therapeutics Inc | Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas |
| CA2775938C (en) * | 2009-09-29 | 2021-08-10 | Oxyrane Uk Limited | Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose |
| WO2013070953A1 (en) * | 2011-11-08 | 2013-05-16 | University Of Washington | Lysosomal enzyme assay methods and compositions |
| KR20140135222A (ko) * | 2012-03-07 | 2014-11-25 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물 |
| WO2014110270A1 (en) * | 2013-01-09 | 2014-07-17 | Amicus Therapeutics, Inc. | Stable parenteral dnj compositions |
| PT3201320T (pt) * | 2014-09-30 | 2024-01-12 | Amicus Therapeutics Inc | Alfa-glucosidase ácida altamente potente com hidratos de carbono intensificados |
| WO2017049161A1 (en) * | 2015-09-18 | 2017-03-23 | Duke University | ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER |
| KR102510941B1 (ko) * | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| MX2018011951A (es) * | 2016-03-30 | 2019-02-13 | Amicus Therapeutics Inc | Metodo para seleccionar proteinas recombinantes ricas en m6p. |
-
2018
- 2018-05-15 JP JP2019562390A patent/JP7193476B2/ja active Active
- 2018-05-15 KR KR1020197036907A patent/KR20200004414A/ko not_active Application Discontinuation
- 2018-05-15 EP EP23164670.4A patent/EP4223310A3/en active Pending
- 2018-05-15 FI FIEP18802722.1T patent/FI3624831T3/fi active
- 2018-05-15 EP EP18802722.1A patent/EP3624831B1/en active Active
- 2018-05-15 HR HRP20230576TT patent/HRP20230576T1/hr unknown
- 2018-05-15 LT LTEPPCT/US2018/032815T patent/LT3624831T/lt unknown
- 2018-05-15 WO PCT/US2018/032815 patent/WO2018213340A1/en active Application Filing
- 2018-05-15 TW TW107116439A patent/TW201900208A/zh unknown
- 2018-05-15 CA CA3063615A patent/CA3063615A1/en active Pending
- 2018-05-15 US US16/613,919 patent/US20210393747A1/en active Pending
- 2018-05-15 BR BR112019024125-6A patent/BR112019024125A2/pt unknown
- 2018-05-15 AU AU2018270925A patent/AU2018270925A1/en active Pending
- 2018-05-15 ES ES18802722T patent/ES2950808T3/es active Active
- 2018-05-15 CN CN201880045818.1A patent/CN111356474A/zh active Pending
- 2018-05-15 IL IL270530A patent/IL270530B2/en unknown
- 2018-05-15 MX MX2019013624A patent/MX2019013624A/es unknown
- 2018-05-15 SI SI201830938T patent/SI3624831T1/sl unknown
- 2018-05-15 PT PT188027221T patent/PT3624831T/pt unknown
- 2018-05-15 HU HUE18802722A patent/HUE062504T2/hu unknown
- 2018-05-15 PL PL18802722.1T patent/PL3624831T3/pl unknown
- 2018-05-15 IL IL310719A patent/IL310719A/en unknown
- 2018-05-15 DK DK18802722.1T patent/DK3624831T5/da active
- 2018-05-15 RS RS20230478A patent/RS64301B1/sr unknown
-
2019
- 2019-11-13 CL CL2019003251A patent/CL2019003251A1/es unknown
- 2019-11-14 ZA ZA2019/07552A patent/ZA201907552B/en unknown
-
2022
- 2022-12-08 JP JP2022196057A patent/JP2023051927A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL270530B2 (en) | 2024-07-01 |
| KR20200004414A (ko) | 2020-01-13 |
| AU2018270925A1 (en) | 2019-11-28 |
| EP3624831A4 (en) | 2021-02-17 |
| EP3624831A1 (en) | 2020-03-25 |
| WO2018213340A1 (en) | 2018-11-22 |
| US20210393747A1 (en) | 2021-12-23 |
| EP4223310A3 (en) | 2023-10-11 |
| PT3624831T (pt) | 2023-07-04 |
| DK3624831T5 (da) | 2024-09-02 |
| CL2019003251A1 (es) | 2020-05-22 |
| HUE062504T2 (hu) | 2023-11-28 |
| TW201900208A (zh) | 2019-01-01 |
| BR112019024125A2 (pt) | 2020-06-02 |
| CN111356474A (zh) | 2020-06-30 |
| IL310719A (en) | 2024-04-01 |
| IL270530A (en) | 2020-01-30 |
| ZA201907552B (en) | 2024-09-25 |
| IL270530B1 (en) | 2024-03-01 |
| EP3624831B1 (en) | 2023-03-29 |
| PL3624831T3 (pl) | 2023-08-14 |
| MX2019013624A (es) | 2020-01-13 |
| ES2950808T3 (es) | 2023-10-13 |
| CA3063615A1 (en) | 2018-11-22 |
| JP2023051927A (ja) | 2023-04-11 |
| SI3624831T1 (sl) | 2023-08-31 |
| EP4223310A2 (en) | 2023-08-09 |
| DK3624831T3 (da) | 2023-06-26 |
| FI3624831T3 (fi) | 2023-06-12 |
| JP7193476B2 (ja) | 2022-12-20 |
| LT3624831T (lt) | 2023-07-10 |
| JP2020519638A (ja) | 2020-07-02 |
| RS64301B1 (sr) | 2023-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230576T1 (hr) | Rekombinantna ljudska kisela alfa-glukozidaza | |
| Liliemark et al. | On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. | |
| US7396825B2 (en) | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | |
| ES2705335T3 (es) | Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados | |
| RU2008142359A (ru) | Композиция человеческого моноклонального антитела к igf-1r | |
| RU2010129481A (ru) | Препарат антитела | |
| US20210008089A1 (en) | Compositions and methods for treating an aggregation disease or disorder | |
| US8398971B2 (en) | Methods, compounds, and compositions for treatment and prophylaxis in the respiratory tract | |
| CN113747899B (zh) | 用于治疗乙型肝炎的Toll样受体激动剂 | |
| JP2020519638A5 (hr) | ||
| CA3236069A1 (en) | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis | |
| CN101559049B (zh) | 肝纤维化抑制剂 | |
| Yang et al. | Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial | |
| JP2023517239A (ja) | コロナウイルス感染症および関連するサイトカイン毒性の治療 | |
| Gorina et al. | PLN-74809, a dual αvβ6/αvβ1, oral, selective integrin inhibitor, is well tolerated and reduces lung TGF-β activity in healthy volunteers | |
| US20070191400A1 (en) | Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives | |
| US20230201249A1 (en) | Compositions incorporating sulfated polysaccharides for inhibiting sars-cov-2 | |
| CN110831598A (zh) | 经鼻给药用医药组合物 | |
| US20230414768A1 (en) | Compositions and methods of treatment for severe hypertriglyceridemia | |
| US8841262B2 (en) | Agent for inhibiting peritoneal membrane thickening | |
| Barrow et al. | The absorption, pharmacodynamics, metabolism and excretion of 14C‐sumatriptan following intranasal administration to the beagle dog | |
| JPS6330290B2 (hr) | ||
| ES2965190T3 (es) | Alfa-glucosidasa ácida aumentada para el tratamiento de la enfermedad de Pompe | |
| CN115400119A (zh) | 马来酸蒿乙醚胺治疗非酒精性脂肪性肝病的医学用途 | |
| RU2275199C1 (ru) | Средство для лечения болезней суставов |